Assessing recurrence risk with ctDNA-based MRD detection in NSCLC patients

[Ketua Dobbs]

Assessing recurrence risk with ctDNA-based MRD detection in NSCLC patients

In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) has emerged as a promising approach to identify individuals at high risk of disease recurrence and potentially guide adjuvant therapy decisions.
Source: Assessing recurrence risk with ctDNA-based MRD detection in NSCLC patients